CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 244 enrolled
Drug / intervention
Bimatoprost Solution 1 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01904721
NCT01904721Phase 2Completed
CompareCT.gov

A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

Allergan·interventional·Posted Jul 22, 2013·Updated Mar 22, 2016

In Brief

A Phase 2 clinical trial evaluating Bimatoprost Solution 1, Bimatoprost Solution 2, and 1 other intervention for Alopecia and 2 related conditions. Completed, enrolled 244 participants across 1 site.

Detailed Summary

This is a safety and efficacy study of bimatoprost in male subjects with androgenic alopecia (AGA).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia, Alopecia, Androgenetic, Baldness
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 22, 2013
Enrollment StartAug 1, 2013
Primary CompletionSep 1, 2014
Study CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 12.9 years ago

Interventions

Bimatoprost Solution 1drug

Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.

Bimatoprost Solution 2drug

Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.

Bimatoprost Vehicledrug

Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.